News
President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...
LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion ...
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
44m
MarketBeat on MSNIs It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
Explore more
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...
4h
India Today on MSNTirzepatide outperforms semaglutide in clinical trial with faster weight lossA global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results